BridgeBio Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $100.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ram Selvaraju has given his Buy rating due to a combination of factors tied to BridgeBio’s advancing pipeline and potential commercial upside. The company has filed its NDA for BBP-418 for LGMD2I/R9 ahead of prior guidance, supported by a pivotal trial that achieved all primary and secondary endpoints and showed a favorable safety profile. If approved, BBP-418 could become the first approved therapy for this subtype of limb-girdle muscular dystrophy, and potentially the first therapy for any LGMD indication, with added value from possible Priority Review status and a monetizable Priority Review Voucher.
Selvaraju also highlights new long-term data for acoramidis from the ATTRibute-CM open-label extension, which show sustained benefit through 54 months in ATTR-CM patients and strengthen the product’s competitive positioning. With acoramidis already launched as Attruby in the U.S. and Beyonttra ex-U.S., he expects the franchise to reach blockbuster status, aided by a long window before tafamidis generics and extensive patent protection on acoramidis itself. Combined, these clinical, regulatory, and intellectual property advantages support his reiterated Buy rating and $100 twelve-month price target.
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 20.7% and a 52.09% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Idorsia Ltd, Aclaris Therapeutics, and Vanda.
In another report released yesterday, William Blair also reiterated a Buy rating on the stock with a $69.00 price target.